Compass Pathways to Present at TD Cowen Healthcare Conference
Event summary
- Compass Pathways management will attend the TD Cowen 46th Annual Healthcare Conference in Boston from March 2-4, 2026.
- The company will participate in a fireside chat on March 3, 2026, at 10:30 AM ET.
- A live audio webcast of the event will be accessible from the Investors section of the Compass website.
- Compass Pathways is developing COMP360, an investigational synthetic psilocybin treatment for treatment-resistant depression (TRD).
- COMP360 has received Breakthrough Therapy designation from the FDA and ILAP designation in the UK.
The big picture
Compass Pathways' participation in the TD Cowen Healthcare Conference underscores the growing interest in psychedelic-assisted therapies for mental health. The company's focus on treatment-resistant depression aligns with broader industry trends toward innovative solutions for conditions that have proven resistant to traditional treatments. The regulatory designations for COMP360 suggest a favorable environment for its development and potential commercialization.
What we're watching
- Regulatory Progress
- How the FDA's Breakthrough Therapy designation and UK's ILAP designation will accelerate COMP360's path to market.
- Market Reception
- Whether investor interest at the TD Cowen conference will translate into increased valuation for Compass Pathways.
- Clinical Development
- The pace at which Compass Pathways can advance COMP360 through late-stage clinical trials.